Back to Journals » Eye and Brain » Volume 8

Current screening and treatments in retinopathy of prematurity in the US

Authors Suelves A, Shulman J

Received 21 September 2015

Accepted for publication 9 January 2016

Published 20 May 2016 Volume 2016:8 Pages 37—43

DOI https://doi.org/10.2147/EB.S94439

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Professor Margaret Wong-Riley


Ana M Suelves, Julia P Shulman

Department of Ophthalmology, New York Medical College, Valhalla, NY, USA

Abstract: Retinopathy of prematurity (ROP) is a complex disease characterized by an aberrant developmental retinal angiogenesis in preterm infants and can carry significant visual morbidity, including retinal detachment and blindness. Though large scale, randomized clinical trials have improved our understanding of the pathophysiology and progression of the disease, the management of ROP remains a challenge for ophthalmologists. This review addresses the up-to-date screening approach, diagnosis, and treatment guidelines for ROP in the US.

Keywords:
retinopathy of prematurity, retinal vascular development, vascular endothelial growth factor, ETROP, BEAT-ROP, eROP

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]